Stay updated with breaking news from Trial Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Project Data Sphere's open access data platform has achieved a major milestone: Boosting the impact of oncology research by contributing to publication of more than 100 peer-reviewed articles that impact research and clinical practice.
Home / Top News / Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021 Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021 AC – Inflammation was Mild and Decreasing over Time in Cohort 3 AC – Inflammation was Mild and Decreasing over Time in Cohort 3 VC – Inflammation was Mild and Decreasing over Time in Cohort 3 VC – Inflam...
Any wastage of Covaxin would be on you, the state has told the health ministry. Speaking to ET, Chhattisgarh health minister T S Singh Deo said, “We have written to the ministry apprising them of our issues with using Covaxin.
(3) LONDON (dpa-AFX) - Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork's progress with ZW49 study. Read on. 1. Applied Genetic Throws Light on Achromatopsia Trials Applied Genetic Technologies Corp.'s (AGTC) phase I/II clinical trials evaluating AAV gene therapy product candidates in patients with achromatopsia caused by CNGB3 or CNGA3 mutations, dubbed ACHMB3 and ACHMA3 trials, have provided for the first time quan...